Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Chemical modification or the reaction product thereof – e.g.,...
Reexamination Certificate
1998-02-09
2002-06-25
Davenport, Avis M. (Department: 1653)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Chemical modification or the reaction product thereof, e.g.,...
C530S362000, C424S001110, C424S193100, C514S002600, C514S021800, C552S200000, C552S227000
Reexamination Certificate
active
06410695
ABSTRACT:
FIELD OF THE INVENTION
The present invention relates to a conjugate for individually dosing pharmaceutical preparations, a process for the production of such a conjugate as well as its use.
BACKGROUND OF THE INVENTION
For a long time there has been a great demand to individually dose pharmaceutical preparations, i.e., accurately adapt their dose to a patient's therapy course. This need is given particularly when chemotherapeutic agents are used. Many attempts have been made to achieve the above. However, the attempts have only showed little success by now.
BRIEF DESCRIPTION OF THE INVENTION
Therefore, it is an object of the present invention to provide for individually dosing pharmaceutical preparations. According to the invention this is achieved by a conjugate which comprises an active substance and a compound having a binding site for metallic compounds.
The expression “active substance” comprises substances of any kind which can be used for treating and/or diagnosing a disease, particularly a tumor, an infectious disease, skin disease and a disease of the immune system.
Examples of such substances include chemotherapeutic agents, e.g., antibiotics, virostatics, antiprotozoals and cytostatic agents. Examples of antibiotics include sulfonamides, tetracyclines, e.g., 7-chlorotetracycline, fusidic acid, gyrase inhibitors, e.g., quinolones, amphotericin, isoniazid, pyrazine 2-carboxylic acid, and pyrazinamide. Examples of virostatics include amantadine and rimantadine. Examples of antiprotozoals are mefloquine and primaquine. Examples of cytostatic agents are anthracyclines, e.g., doxorubicin, topoisomerase inhibitors, mitomycin A and C, bleomycinic acid, chlorambucil, melphalan and antifolates e.g., methotrexate. Furthermore such a substance may be an aminoanthraquinone such as celliton blue and acid black. Moreover, such a substance may be a photoactive substance, e.g., a porphyrin such as o-, m- and/or p-tetrahydroxyphenylporphine, o, m- and/or p-tetracarboxyphenylporphine and o-, m- and/or p-tetrasulfophenylporphine, a chlorin such as o-, m- and/or p-tetrabydroxyphenylchlorin, o-, m- and/or tetracarboxyphenylchlorin and o-, m- and/or p-tetrasulfophenylchlorin, or a bacteriochlorin, o-, m- and/or p-tetrahydroxyphenylbacteriochlorin such as o-, m- and/or p-tetracarboxyphenylbacteriochlorin, and o-, m- and/or p-tetrasulfophenylbacteriochlorin. In addition, such a substance may be a contrast medium for fluorospectroscopy, e.g., trifluoroacetic acid, nuclear resonance scanning or scintiscanning.
One or more of the above substances and/or analogues or derivatives thereof are present in a conjugate according to the invention. If several are present, they may be the same or differ from one another.
The expression “compound having a binding site for metallic compounds” includes compounds of any kind which have binding sites for metallic compounds. Examples of such binding sites include hydroxyl groups, particularly C-atoms bound hydroxyl groups, carbonyl and carboxyl groups. The compound may have one or more binding sites. The compound has preferably 2, more preferably 3 to 6, binding sites. If several binding sites are present, they may be the same or differ from one another. Examples of the above compounds are ethylenediaminetetraacetate (EDTA), diethylenetri-aminepentaacetate (DTPA), triethylenetetraminehexaacetate (TTHE), alizarin and derivatives thereof.
One or more of the above compounds are present in a conjugate according to the invention. If several are present, they may be the same or differ from one another. The presence of several of the above compounds supports the water solubility of the conjugate and its ability to bind metallic compounds.
REFERENCES:
patent: 4118468 (1978-10-01), Strecker et al.
patent: 4339426 (1982-07-01), Meares et al.
patent: 0 217 577 (1987-04-01), None
patent: 0 243 929 (1987-11-01), None
patent: WO 89/00062 (1989-01-01), None
patent: WO 89/05853 (1989-06-01), None
patent: WO 91/01144 (1991-02-01), None
patent: WO 91/14459 (1991-10-01), None
patent: WO 93/02105 (1993-02-01), None
patent: WO 93/02192 (1993-02-01), None
patent: WO 93/18160 (1993-09-01), None
patent: WO 94/08624 (1994-04-01), None
patent: WO 95/19791 (1995-07-01), None
patent: WO 95/29707 (1995-11-01), None
patent: WO 96/10422 (1996-04-01), None
Kato, et al., Chemical Abstracts, 121(4): Abstract No. 42716, (1994).
Sinn, et al., “Design of Compounds Having an Enhanced Tumour Uptake, using Serum Albumin as a Carrier. Part 1”,Nucl. Med. Biiol.—17(8):819-827 (1990).
Nakajima, et al., “In-Labeled Mn-Metalloporphyrin for Tumor Imaging,”Nuel. Med. Biol. —20(2):231-237 (1993).
Sinn, et al., “Radioactive Labeled Photsensitizers for Tumor Diagnostic and Photodynamic Therapy (PDT)”,J. Labelled Comp. Radiopharm—(1993).
Maier-Borst Wolfgang
Schrenk Hans-Hermann
Sinn Hannsjörg
Stehle Gerd
Davenport Avis M.
Deutsches Krebsforschungszentrum Stiftung Des Öffentlichen Recht
Halluin Albert P.
Howrey Simon Arnold & White , LLP
Kung Viola T.
LandOfFree
Individual medicament dosing conjugate does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Individual medicament dosing conjugate, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Individual medicament dosing conjugate will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2942009